Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow Health Inc (HROW) is a leading developer of ophthalmic pharmaceuticals and non-intravenous sedation therapies, addressing critical needs in eyecare and procedural medicine. This dedicated news hub provides investors and healthcare professionals with timely access to official announcements and objective updates about the company's progress.
Our curated collection features earnings reports, regulatory milestones, and product development updates, offering a comprehensive view of HROW's strategic direction. Users will find essential information on FDA approvals, clinical trial results, and partnership announcements that shape the company's position in the pharmaceutical sector.
Key content categories include financial disclosures, research breakthroughs, and manufacturing updates related to compounded medications and sedation therapeutics. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.
Bookmark this page for streamlined access to HROW's latest developments. Check back regularly for authoritative updates on innovations in ocular surface disease treatments and non-IV sedation solutions that demonstrate the company's commitment to advancing patient care.
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has partnered with Harrow (HROW) to launch an authorized generic version of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension). The ophthalmic medication is designed to treat and relieve bacterial eye infections. According to IQVIA data from January 2025, Maxitrol® and its generic equivalents generated annual sales of $20.8 million in the U.S. market.
Harrow (HROW) has expanded its VEVYE® Access for All (VAFA) program to include current Klarity-C Drops® patients, offering VEVYE at $59 per bottle. The expansion allows over 25,000 U.S. patients to convert their Klarity-C prescriptions to FDA-approved VEVYE, a cyclosporine ophthalmic solution 0.1% for dry eye disease treatment.
The program eliminates access barriers like prior authorization and reimbursement delays, while providing free home delivery and a money-back guarantee. Patients can choose between insurance coverage or Harrow's cash price. Klarity-C prescribers can transfer prescriptions through PhilRx's platform in under 5 minutes.
Harrow (HROW) reported strong financial results for Q4 and full-year 2024. The company achieved record Q4 revenues of $66.8 million, up 84% year-over-year, while full-year 2024 revenues reached $199.6 million, representing a 53% increase from 2023.
Q4 2024 highlights include GAAP net income of $6.8 million and Adjusted EBITDA of $22.5 million. For the full year 2024, the company reported a GAAP net loss of $(17.5) million and Adjusted EBITDA of $40.3 million.
Notable operational achievements include over 40% quarter-over-quarter growth in both IHEEZO unit demand and VEVYE prescriptions. The company announced its VEVYE Access for All program to drive market share expansion in 2025. Additionally, TRIESENCE received transitional pass-through approval, significantly expanding its market opportunity. Management provided 2025 revenue guidance of 'more than $280 million,' projecting over 40% growth.
Harrow (HROW), a leading North American eyecare pharmaceutical company, has scheduled the release of its fourth quarter and audited financial results for the year ended December 31, 2024. The announcement will be made after market close on March 27, 2025.
The company will publish its fourth quarter Letter to Stockholders on its website's Investors section. A conference call and live webcast are scheduled for March 28, 2025, at 8:00 a.m. Eastern Time to discuss results and provide business updates. Interested participants can access the conference via webcast through Harrow's website or register in advance for telephone access. A replay will be archived on the company's website for one year.
Harrow (HROW) has received approval from the Centers for Medicare & Medicaid Services (CMS) for transitional pass-through reimbursement status for TRIESENCE®, their preservative-free synthetic corticosteroid.
Starting April 1, 2025, TRIESENCE will receive separate reimbursement outside surgical bundled payments in both Ambulatory Surgery Centers and Hospital Outpatient Departments for three years. CMS will reimburse at Average Sales Price plus 6%. The drug previously received a permanent J-Code (J3300), making it the only preservative-free synthetic corticosteroid with separate reimbursement across all traditional care settings.
TRIESENCE is FDA-approved for visualization during vitrectomy and treating ocular inflammatory conditions unresponsive to topical corticosteroids. The drug is available in 40mg/mL single-use vials through major pharmaceutical distributors.
Harrow (HROW) has announced a delay in releasing its audited financial results for Q4 and full-year 2024, as their new independent auditor requires additional time to complete the audit process. The company emphasizes this delay is not due to any disagreements on accounting principles, practices, financial statement disclosure, or auditing procedures.
CEO Mark L. Baum confirmed that Harrow has successfully met the annual leverage ratio term under their senior secured loan agreement, avoiding the issuance of warrants to lenders. The company has provided revenue guidance for 2025 of over $280 million, with growth expected to be primarily driven by their higher-margin branded business.
Harrow (NASDAQ: HROW) has launched VEVYE® Access for All, a groundbreaking program making their dry eye disease therapy more accessible and affordable. The initiative, available through PhilRx specialty pharmacy, guarantees eligible patients access to VEVYE (cyclosporine ophthalmic solution) 0.1% for $59.
Key program benefits include:
- No prior authorization requirements
- Expedited prescription processing with free home delivery
- First prescription available for as low as $0 for eligible patients
- Refills at $59 per bottle with additional discounts for 3-bottle orders
- Money-back guarantee
The program aims to eliminate barriers created by insurance middlemen, streamline the prescribing process, and ensure quick, affordable access to treatment. The initiative is immediately available nationwide through PhilRx, with plans to expand to other pharmacy networks.
Harrow (HROW) has executed a five-year strategic supply and development agreement for TRIESENCE®, a preservative-free synthetic corticosteroid approved by the FDA for visualization during vitrectomy and treatment of certain ocular inflammatory conditions. The agreement is with the current contract manufacturing organization that has over 15 years of experience with TRIESENCE manufacturing.
The company aims to ensure continuous supply of TRIESENCE, which had previously been on the FDA's Drug Shortage List for over five years. Additionally, Harrow has initiated development of a next-generation version of TRIESENCE, with plans to submit a new drug application (NDA) to the FDA by the end of 2027.
Harrow (HROW), a leading North American eyecare pharmaceutical company, has scheduled its fourth quarter and year-end 2024 financial results announcement for March 17, 2025, after market close. The company will simultaneously release its fourth quarter Letter to Stockholders on its website.
A conference call and live webcast are planned for March 18, 2025, at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Investors can access the conference call through the company's website or register for telephone participation, which will provide them with a unique dial-in number and PIN.
Harrow (HROW) has announced a strategic partnership with Cencora (COR) to launch the 'Harrow Cares' program, aimed at improving accessibility and affordability of IHEEZO® and TRIESENCE® for retina specialists and their patients. The program offers comprehensive support services through a state-of-the-art patient support hub.
The initiative includes multiple key features: streamlined enrollment through various channels, real-time benefit verifications for rapid treatment access, flexible affordability options including commercial copay assistance with patients paying as little as $0, and ongoing support services including patient welcome calls and prior authorization denial assistance.
This partnership represents Harrow's strategic focus on expanding its presence in the U.S. retina market and demonstrates the company's commitment to improving healthcare accessibility while driving better patient outcomes.
